Two European and multiple US biotechs priced sizeable offerings this week, reviving investor interest in drug-company IPOs. Belgium-based Agomab and ocular-therapy developer SpyGlass together raised about $350 million in separate Nasdaq listings, while California-based Eikon Therapeutics sold $381 million in shares in an upsized debut. Biopharma investors flagged the cluster of offerings as the busiest stretch for new biotech listings since early 2024. The companies plan to deploy proceeds into clinical development and platform expansion: Agomab will accelerate inflammatory-disease programs; SpyGlass targets long-acting ocular therapies; and Eikon aims to fund multiple oncology programs, including TLR7/8 and PARP-focused assets. Market participants note that larger, later-stage or well-backed biotechs are driving the revival, supported by crossover investor interest and a handful of strong 2025 IPO performances that restored confidence. Context: an IPO rebound matters because public financing can reshape clinical timelines and partnership dynamics across the sector. For readers tracking capital markets, these deals suggest a narrowing gap between private cash and public exit windows, especially for companies with near-term clinical catalysts.